|Articles|April 15, 2003

BioPharm International

  • BioPharm International-04-01-2003
  • Volume 16
  • Issue 4

Inside Washington: GMP Progress Report

Author(s)Jill Wechsler

by Jill Wechsler, BioPharm International Six months into its initiative to update manufacturing regulations, FDA announces a raft of changes covering warning letters, inspections, and comparability ? plus a fresh start on Part 11.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 22 years ago

Virus Inactivation in the 1990s and into the 21st Century

over 22 years ago

Using Peptide Maps as Identity and Purity Tests for Lot Release Testing of Recombinant Therapeutic Proteins

over 22 years ago

Getting Ready for Risk-Based GMPs

over 22 years ago

GMP Issues: Breaking Ground

over 22 years ago

Guest Editorial: Benchmarking Biotech

over 22 years ago

Optimized Nutrient Additives for Fed-Batch Cultures

over 22 years ago

Commercial Production of Transgenic Crops Genetically Engineered to Produce Pharmaceuticals

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!